This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
CULPRIT-SHOCK was a randomized phase 4 treatment trial evaluating culprit lesion only PCI versus immediate multivessel PCI in patients with cardiogenic shock associated with acute myocardial infarction.
| Feature | CULPRIT-SHOCK |
|---|---|
| Condition | Cardiogenic Shock; Acute Myocardial Infarction; Complications |
| Design | Randomized, parallel, open-label |
| Primary purpose | Treatment |
| Lead sponsor | University of Luebeck |
| Enrollment | 706 |
2. Clinical Question
Population
Patients with cardiogenic shock associated with acute myocardial infarction.
Intervention
Culprit lesion only PCI.
Comparator
Immediate multivessel PCI.
Primary question
Does the PCI strategy affect the registry-defined primary endpoint at 30 days?
3. Trial Design
Randomized
Parallel
None
2017-07
Culprit Lesion Only PCI
Procedure intervention arm.
Immediate Multivessel PCI
Procedure comparator arm.
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Primary endpoint | 30-day mortality and/or severe renal failure requiring renal replacement therapy | 30 days |
5. Planned Analysis
The registry identifies the primary endpoint as a composite endpoint combining mortality and severe renal failure requiring renal replacement therapy at 30 days. For randomized clinical trials with binary composite outcomes, analysis commonly involves comparing event proportions between randomized groups using an appropriate hypothesis-testing framework and effect estimate with uncertainty intervals.
No formal statistical analyses were posted to ClinicalTrials.gov.
6. Statistical Methodology
Composite endpoints
A composite endpoint combines multiple clinical events into a single outcome measure. This approach can increase the number of observed events, but interpretation depends on the contribution of each component and whether the components represent outcomes of similar clinical importance.
Randomization
Random allocation is designed to balance known and unknown prognostic factors between groups, allowing differences in outcomes to be interpreted as comparisons between assigned strategies.
Binary outcome analysis
A 30-day composite endpoint is typically summarized using event rates, relative measures such as risk ratios or odds ratios, and confidence intervals describing statistical uncertainty.
7. Statistical Methods Explained
Why use a randomized design?
Randomization reduces systematic differences between treatment groups and supports causal interpretation of observed differences in outcomes.
Why combine mortality and renal failure?
Composite endpoints can capture multiple clinically important events. Interpretation requires understanding whether treatment effects are similar across components.
What does the 30-day timeframe mean?
The endpoint evaluates outcomes occurring within the prespecified 30-day period after treatment assignment.
Why are confidence intervals important?
Confidence intervals describe the precision of an estimated treatment effect and should be interpreted together with the estimate itself.
8. Limitations
- The registry does not report posted statistical analyses for the primary endpoint.
- The ClinicalTrials.gov record does not report subgroup analyses, safety results by arm, missing-data methods, multiplicity procedures, or interim-analysis details.
- Composite endpoints require careful interpretation because individual components may differ in frequency and clinical meaning.
9. Why This Trial Matters Statistically
| Concept | How it appears in CULPRIT-SHOCK |
|---|---|
| Randomization | Randomized allocation to two PCI strategies |
| Parallel design | Two-arm treatment comparison |
| Composite endpoint | Mortality and severe renal failure requiring renal replacement therapy |
| Time frame | 30-day clinical assessment |
| Treatment comparison | Culprit lesion only PCI versus immediate multivessel PCI |